NONBREAST SECOND MALIGNANCIES AFTER TREATMENT OF PRIMARY BREAST CANCER

被引:20
|
作者
Yadav, Budhi S. [1 ]
Sharma, Suresh C. [1 ]
Patel, Firuza D. [1 ]
Ghoshal, Sushmita [1 ]
Kapoor, Rakesh [1 ]
Kumar, Rajinder [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Dept Radiotherapy, Chandigarh 160039, India
关键词
Second malignancy; Breast cancer; Radiotherapy; Chemotherapy; MULTIPLE PRIMARY CANCERS; RADIATION-THERAPY;
D O I
10.1016/j.ijrobp.2008.07.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the incidence and risk factors for nonbreast second malignancies (NBSMs) in women after treatment for primary breast cancer. Methods and Materials: Between January 1985 and December 1995, a total of 1,084 breast cancer patients were analyzed. for NBSMs. Detailed analysis was carried out for age, family history, disease stage, radiation therapy, chemotherapy, hormone therapy, other clinical/pathologic characteristics, and site of NBSMs. The Cox proportional hazard regression model was used to estimate the relative risk of NBSMs. Results: Median follow-up was 12 years. In total, 33 cases of NBSMs were noted in 29 patients. The overall incidence of NBSM was 3%, and the median time for NBSMs was 7 years. The most common NBSMs were gynecologic (22 patients), gastrointestinal (4 patients), head and neck (3 patients), hematologic (2 patients), lung (1 patient), and thyroid 0 patient). The NBSMs rate at 12 years was 2.4% for both mastectomy and radiation therapy groups. In the subset of patients less than 45 years of age at the time of treatment, the NBSMs rate was 0.7% as compared with 4.6% in patients more than 45 years of age (p = 0.001). Statistically significant higher incidences of endometrial and ovarian cancer were seen in patients with hormonal therapy (5.2%) as compared with patients without hormonal therapy (1.8%,p = 0.002). Women with a family history of breast cancer had a higher incidence (6%) of endometrial and ovarian malignancy compared with women without such a history (2.1%,p = 0.003). Chemotherapy did not affect the risk of second malignancy. Conclusion: The most common NBSMs in this study were gynecologic. Family history of breast cancer was a high risk factor for NBSMs. No risk of NBSMs with radiotherapy was observed. (C) 2009 Elsevier Inc.
引用
收藏
页码:1489 / 1492
页数:4
相关论文
共 50 条
  • [21] Breast cancer risk factors and second primary malignancies among women with breast cancer
    Amy Trentham-Dietz
    Polly A. Newcomb
    Hazel B. Nichols
    John M. Hampton
    Breast Cancer Research and Treatment, 2007, 105 : 195 - 207
  • [22] Risks of second malignancies after breast cancer treatment: Long-term results
    Bazire, L.
    De Rycke, Y.
    Asselain, B.
    Fourquet, A.
    Kirova, Y. M.
    CANCER RADIOTHERAPIE, 2017, 21 (01): : 10 - 15
  • [23] Second malignancies after LH-RH analogues treatment for early breast cancer
    de Matteis, A
    Landi, G
    Nuzzo, F
    Labonia, V
    Rossi, E
    Perrone, F
    D'Aiuto, G
    Capasso, I
    Longo, C
    Pizzorusso, M
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S209 - S209
  • [24] Acute leukemia/MDS after treatment of breast cancer secondary or second malignancies.
    Wong, GC
    Kantarjian, HM
    Beran, M
    BLOOD, 1998, 92 (10) : 236A - 236A
  • [25] SECOND PRIMARY MALIGNANCIES IN CHILDREN AND ADOLESCENTS AFTER RETINOBLASTOMA TREATMENT
    Temming, P.
    Viehmann, A.
    Arendt, M.
    Eisele, L.
    Spix, C.
    Bornfeld, N.
    Sauerwein, W.
    Joeckel, K. H.
    Lohmann, D.
    PEDIATRIC BLOOD & CANCER, 2015, 62 : S232 - S232
  • [26] Second malignancies after breast cancer: The impact of adjuvant therapy
    Dong, Chunhui
    Chen, Ling
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 331 - 336
  • [27] Childhood Cancer: Occurrence, Treatment and Risk of Second Primary Malignancies
    Zahnreich, Sebastian
    Schmidberger, Heinz
    CANCERS, 2021, 13 (11)
  • [28] Incidence of second primary malignancies in women with different stages of breast cancer
    Lin, Cheng-Yao
    Hsiao, Sheng-Yen
    Huang, Wen-Tsung
    Tsao, Chao-Jung
    Ho, Chung-Han
    Su, Shih-Bin
    Guo, How-Ran
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [29] The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer
    Brown, Aaron. P.
    Chen, Jergin
    Hitchcock, Ying J.
    Szabo, Aniko
    Shrieve, Dennis C.
    Tward, Jonathan. D.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (02): : 504 - 515
  • [30] Risk of second primary malignancies after definitive treatment for esophageal cancer: A competing risk analysis
    Mitani, Seiichiro
    Kadowaki, Shigenori
    Oze, Isao
    Masuishi, Toshiki
    Narita, Yukiya
    Bando, Hideaki
    Oonishi, Sachiyo
    Hirayama, Yutaka
    Tanaka, Tsutomu
    Tajika, Masahiro
    Koide, Yutaro
    Kodaira, Takeshi
    Abe, Tetsuya
    Muro, Kei
    CANCER MEDICINE, 2020, 9 (01): : 394 - 400